Flurpiridaz PET MPI data reveal lower dose than conventional SPECT

Kathy Mahdoubi | | Health Imaging | Molecular Imaging

Myocardial perfusion imaging (MPI) with PET and F-18 flurpiridaz may reduce radiation dose while still providing comparable image quality to SPECT, the current standard, according to a study presented at the recent American Society of Nuclear Cardiology (ASNC) Annual Scientific Session held in Boston from Sept 18-21.

F-18 flurpiridaz is scheduled to go through three phase III trials, announced makers Lantheus Medical Imaging. The data presented was procured from the first of these trials. 

“Analysis of the first phase III clinical study has demonstrated a statistically and clinically significant reduction in radiation exposure achieved with F-18 flurpiridaz as compared with standard SPECT imaging,” said Jamshid Maddahi, MD, lead study author and presenter at the ASNC meeting, in a press release. “This was in the presence of significant improvements in image quality and diagnostic certainty. These results provide additional evidence for F-18 flurpiridaz as a potentially important new advancement in nuclear cardiology.”

The second phase III clinical trial is in the first stages of planning. Further research is required before F-18 flurpiridaz could obtain regulatory approval and commercialization for myocardial perfusion imaging.  

 

Kathy Mahdoubi

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.